Sangamo BioSciences Inc. (SGMO) Company Profile
Sangamo Biosciences, Inc. engages in the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP transcription factors (ZFP TFs), proteins that could be used to turn genes on or off; and ZFP nucleases (ZFNs), proteins that enable to modify DNA sequences in various ways. The company?s principal ZFP therapeutic include SB-509, a plasmid formulation of a ZFP TF activator of the vascular endothelial growth factor-A (VEGF-A) gene that is in a Phase 2b clinical trial for the treatment of severe diabetic neuropathy; and in a Phase 2 clinical trial in for the treatment of amyotrophic lateral sclerosis, as well as in preclinical animal studies for spinal cord injury, traumatic brain injury, and stroke. It is also developing SB-728-T, a ZFN-modified T-cell product, which is in Phase 1/2 clinical trial and two Phase 1 trials for the treatment of HI V/AIDS. In addition, the company develops SB-313xTZ, a ZFN-based therapeutic that is in Phase 1 clinical trial for the treatment of glioblastoma multiforme, a type of brain cancer. Further, it has preclinical development programs of ZFP therapeutics in the areas of Parkinson?s disease, hemophilia B, and neuropathic pain; and neuroregenerative programs in spinal cord injury, traumatic brain injury, and stroke. Additionally, the company has research stage programs in the areas of monogenic diseases and genetic conditions that result from a defect in a single gene, including hemophilia and other hemoglobinopathies, and immunodeficiencies. It has collaboration agreements with Sigma-Aldrich Corporation; Dow AgroSciences LLC; Pfizer Inc.; Genentech, Inc.; Open Monoclonal Technology, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was founded in 1995 and is headquartered in Richmond, California.
News about SGMO
Why Sangamo Therapeutics Stock Is Spiking Today
What happened Shares of the gene therapy company Sangamo Therapeutics (NASDAQ:SGMO) rose by as much as 14.6% today on heavier than normal volume. The catalyst? Sangamo's shares are trading upward in sympathy with nearly all major gene therapy compani...Read More>>>
Is Gene Editing Dangerous? 4 Things You Should Know
"Here be dragons." Those words, included on uncharted territory of a globe made in the 16th century, underscore how people have historically associated danger with the unknown. This fear also often manifests itself with major new technological advanc...Read More>>>
Sangamo Therapeutics Inc (SGMO) Expected to Post Quarterly Sales of $31.13 Million
Wall Street brokerages forecast that Sangamo Therapeutics Inc (NASDAQ:SGMO) will report sales of $31.13 million for the current quarter, according to Zacks. Two analysts have provided estimates for Sangamo Therapeutics’ earnings, with the highe...Read More>>>
Cellectis: Will Focus On Universal CAR-T Payoff?
I believe gene therapy will become a mainstay in treating, and maybe curing, many of our most devastating and intractable illnesses. Scott Gottlieb, FDA Commissioner Cellectis S.A. (CLLS) announced news in 2015 that made me sit up and take notice ...Read More>>>
CRISPR Therapeutics: Clinical Debut Sets Up Round 1 Of Editing Battle Royale
This article is part of a series on genomic medicine which is poised to transform healthcare over the next two decades. The first article entitled Genomic Medicine: Catch the Gene Therapy Wave is a primer providing context for company-specific art...Read More>>>